LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

2,584
Mkt Cap
$4.04B
Volume
386.00
52W High
$212.49
52W Low
$93.58
PE Ratio
34.71
LGND Fundamentals
Price
$202.55
Prev Close
$198.31
Open
$197.20
50D MA
$194.12
Beta
1.00
Avg. Volume
185,322.81
EPS (Annual)
$6.13
P/B
3.94
Rev/Employee
$5.7M
$3,554.96
Loading...
Loading...
News
all
press releases
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts
read more...
Benzinga·4d ago
News Placeholder
More News
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Oppenheimer Analyst Says
Oppenheimer upped their price objective on shares of Ligand Pharmaceuticals from $275.00 to $277.00 and gave the company an "outperform" rating in a report on Friday...
MarketBeat·4d ago
News Placeholder
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND
Vanguard Group Inc. reduced its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with...
MarketBeat·4d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS
Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating the...
MarketBeat·4d ago
News Placeholder
Ligand Pharmaceuticals Q4 Earnings Call Highlights
Ligand Pharmaceuticals (NASDAQ:LGND) reported what management described as a defining and breakout year in 2025, driven by growth across its royalty portfolio and what it called a lean operating...
MarketBeat·5d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance
Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2026 earnings guidance. The company provided EPS guidance of 8.000-9.000 for the period, compared to the consensus estimate of 4.850. The company...
MarketBeat·5d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00
HC Wainwright raised their price objective on shares of Ligand Pharmaceuticals from $231.00 to $239.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·7d ago
News Placeholder
State of New Jersey Common Pension Fund D Takes $2.40 Million Position in Ligand Pharmaceuticals Incorporated $LGND
State of New Jersey Common Pension Fund D acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the third quarter, according to the company in its most recent 13F...
MarketBeat·9d ago
News Placeholder
Isthmus Partners LLC Sells 7,775 Shares of Ligand Pharmaceuticals Incorporated $LGND
Isthmus Partners LLC cut its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.9% in the 3rd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·10d ago
News Placeholder
CenterBook Partners LP Has $1.14 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
CenterBook Partners LP lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 52.2% during the third quarter, according to the company in its most recent...
MarketBeat·10d ago
<
1
2
...
>

Latest LGND News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.